{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Everolimus+%28RAD001%29", "query": { "intervention": "Everolimus (RAD001)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 268, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Everolimus+%28RAD001%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T10:26:14.874Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01031381", "title": "Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-08-30", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031381" }, { "nct_id": "NCT01252251", "title": "RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "RAD001 (Everolimus) and Pasireotide (SOM230) LAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-11", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252251" }, { "nct_id": "NCT01289912", "title": "Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tuberous Sclerosis Complex" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mustafa Sahin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 52, "start_date": "2011-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289912" }, { "nct_id": "NCT04665739", "title": "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Neuroendocrine Tumor", "Functioning Lung Neuroendocrine Tumor", "Locally Advanced Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor G1", "Lung Neuroendocrine Tumor G2", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Non-Functioning Lung Neuroendocrine Tumor", "Recurrent Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-02-03", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665739" }, { "nct_id": "NCT02321501", "title": "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Positive", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "ROS1 Gene Rearrangement", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-06-22", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02321501" }, { "nct_id": "NCT01797523", "title": "A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2013-10-07", "completion_date": "2026-02-04", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 6, "location_summary": "Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas", "locations": [ { "city": "Pensacola", "state": "Florida" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01797523" }, { "nct_id": "NCT00849550", "title": "Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Cancer" ], "interventions": [ { "name": "capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Hurwitz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2009-07", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-24", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 3, "location_summary": "Harvey, Illinois • Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Harvey", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849550" }, { "nct_id": "NCT00107237", "title": "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "AEE788", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2003-10", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2013-06-12", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 3, "location_summary": "Los Angeles, California • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107237" }, { "nct_id": "NCT00474929", "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 103, "start_date": "2007-08-29", "completion_date": "2019-08-08", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474929" }, { "nct_id": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2013-05-31", "completion_date": "2017-09-12", "has_results": true, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-10-02T10:26:14.874Z", "location_count": 25, "location_summary": "Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Rockford", "state": "Illinois" }, { "city": "Ames", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01797120" } ] }